Clinical Trials Logo

Clinical Trial Summary

- To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer which participated in double blind study.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00247663
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date December 1999

See also
  Status Clinical Trial Phase
Completed NCT00237198 - Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment Phase 2
Completed NCT00237211 - Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer Phase 2